Questionnaire summary
| Questions and answer options |
| General characteristics of the respondents |
| Which is your gender? |
| Which is your age? |
| <30 years 30–39 years 40–49 years 50–59 years ≥60 years |
| Which country do you currently work in? |
| In which setting do you currently work? |
| What is your specialty? |
| Indications, legal constraints and toxicity of new drugs in thoracic oncology |
| With regard to new systemic therapies in thoracic oncology, are you aware of the following? |
| The legal process for drug recognition in the European Community The European Medicines Agency (EMA) |
| Are you aware of the clinical indications for the following systemic therapies in lung cancer? |
| EGFR TKIs ALK inhibitors ROS-1 inhibitors Anti-EGFR antibodies Anti-angiogenic antibodies (e.g. anti-VEGF) Immunotherapy (PD1/PDL1 axis) Immunotherapy (CTLA4 axis) Monoclonal antibodies Oral angiogenic inhibitors |
| Are currently you prescribing any of the following systemic therapies in lung cancer? |
| EGFR TKIs ALK inhibitors ROS-1 inhibitors Anti-EGFR antibodies Anti-angiogenic antibodies (e.g.anti-VEGF) Immunotherapy (PD1/PDL1 axis) Immunotherapy (CTLA4 axis) Monoclonal antibodies Oral angiogenic inhibitors |
| Do you feel you have a good understanding of the toxicity profile of the following systemic therapies in lung cancer? |
| EGFR TKIs ALK inhibitors ROS-1 inhibitors Anti-EGFR antibodies Anti-angiogenic antibodies (e.g.anti-VEGF) Immunotherapy (PD1/PDL1 axis) Immunotherapy (CTLA4 axis) Monoclonal antibodies Oral angiogenic inhibitors |
| Which of the following are potential pulmonary complications from the new systemic therapies in lung cancer listed above? |
| Haemoptysis Bronchospasm Pleural effusion Interstitial lung disease Pneumonia |
| At your current place of work, which is the primary specialty responsible for managing toxicity from new systemic therapies in lung cancer? |
| Pneumology Medical oncology Organ-specific specialist (depending on the site of toxicity) General internal medicine physician Oncology nurse |
| The To”X”csin Project: would you use an online platform such as this? |
| Yes No Not sure |
| What do you think is the most important function of an online platform such as this? |
| What type of toxicity information should be reported on? |
| Only lung toxicity All toxicity |
| At your institution, would you be willing to seek approval from a regulatory board and ethics committee to submit patient data to the To”X”csin system? |
| Yes No Maybe |
EGFR: epidermal growth factor receptor; TKI: tyrosine kinase inhibitor; ALK: anaplastic lymphoma kinase; ROS-1: ROS proto-oncogene 1; VEGF: vascular endothelial growth factor; PD1: programmed cell death 1; PDL1: programmed death ligand 1; CTLA4: cytotoxic T-lymphocyte-associated protein 4.